Menu
1 min read · estimated
APPROVED USE
What FDA approved
Single-agent treatment of recurrent or metastatic cervical cancer with PD-L1 combined positive score of at least 1 by an FDA-approved test, after progression during or after chemotherapy.
LAMPGEN ANALYSIS
Why it matters
This converts the post-chemotherapy monotherapy indication and is distinct from the same-day combination approval.
What research teams should watch
Separate monotherapy from the first-line combination in abstraction and retain the prior chemotherapy date.
PRIMARY RECORDS